Skip to content
AnalystLens

QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Jan 12, 2026)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed January 12, 2026
Period End
January 12, 2026
Security
DGX
In the record · 2016–202610-K1110-Q328-K130

DGX filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 130 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’16May ’16
  2. Leadership change8-K · Jun ’20Jun ’20
  3. Leadership change8-K · Jul ’22Jul ’22
  4. Material agreement8-K · Aug ’24Aug ’24

01—Abstract

Summary

Summary of the 8-K filed January 12, 2026. Cited figures are marked; the original filing is the authoritative source.

Quest Diagnostics (DGX) filed this Form 8-K on January 12, 2026 to furnish the slide presentation CEO Jim Davis delivered at the 44th Annual J.P.

Morgan Healthcare Conference. The filing is a Regulation FD disclosure rather than an earnings release: it contains no new quarterly results, no revised guidance for a specific period, and no transaction or governance change. Its substance is management's strategic framing: a roughly $89 billiona U.S. lab market growing 1%-4% annually, a Canadian business (LifeLabs) in a roughly $5 billion market, and a long-term outlook beyond 2025 of 4%-5% revenue CAGR and 7%-9% adjusted EPS CAGR, with operating margin expansion of 75-150 basis points by the end of 2027.

The capital allocation framework is the most investor-relevant element. For 2025-2027, management targets $4.5b-5.0 billion in operating cash flow, $1.5-1.7 billion in capital expenditures, and $3.0-3.3 billion in free cash flow. Planned uses are about $1.5 billion for acquisitions, roughly $1.0 billion in dividends, and about $0.7 billion in share repurchases to offset option dilution.

Management says these targets are consistent with its March 2025 Investor Day, which signals continuity rather than a change in plans. M&A is presented as a central growth lever, with about $2.8 billionc deployed over three years to generate over $1 billion in annual revenue, and acquisitions are screened for year-one adjusted EPS accretion and at least 10% ROIC by year three.

Growth narratives emphasize advanced diagnostics (about $1 billiond in 2025 revenue across five clinical areas, with double-digit growth expected), the Collaborative Lab Solutions hospital-partnership business (about $800 million in 2025 revenue, targeted at about $1 billion in 2026 including Corewell Health), consumer-initiated testing and wellness partnerships, and a 3% annual productivity target through the Invigorate program. The presentation contains no quantified 2026 guidance, and the adjusted EPS and operating margin figures are non-GAAP with no GAAP reconciliation provided, which investors should keep in mind when weighing these targets.

02—Key points

Key Highlights

  1. Long-term outlook beyond 2025: 4%-5% total revenue CAGR (including 1%-2% from acquisitions) and 7%-9% adjusted EPS CAGR, with operating margins expanding 75-150 bps by end of 2027.
  2. 2025-2027 capital plan: $4.5-5.0B operating cash flow, $3.0-3.3B free cash flow, ~$1.5B for acquisitions, ~$1.0B dividends, and ~$0.7B share repurchases to offset option dilution.
  3. M&A framework: ~$2.8B deployed over three years to generate over $1B in annual revenue, with acquisitions required to be accretive to adjusted EPS in year one and to exceed 10% ROIC by year three.
  4. Collaborative Lab Solutions (hospital lab management) generated ~$800M in 2025 revenue and is expected to reach ~$1B in 2026, including the Corewell Health outreach arrangement.
  5. Advanced diagnostics across five clinical areas (cardiometabolic, autoimmune, brain health, oncology, women's health) generated ~$1B in 2025 and are expected to grow at double-digit rates.
  6. Market positioning: Quest holds about 12% of the ~$89B U.S. lab market, with physician channel growth of 4%-5% CAGR and hospital channel growth of 5%-6% CAGR cited as above-market targets.
  7. The filing is a Regulation FD presentation with no new quarterly results or specific 2026 guidance, and it relies on non-GAAP measures without GAAP reconciliations.

03—Questions

Frequently Asked Questions

  1. Did Quest Diagnostics report new financial results or change its guidance in this filing?

    No. The 8-K furnishes a presentation delivered at the J.P. Morgan Healthcare Conference under Regulation FD. It reiterates long-term targets (4%-5% revenue CAGR, 7%-9% adjusted EPS CAGR) and the 2025-2027 capital plan, but it does not report new quarterly results or issue specific 2026 guidance.

  2. How is Quest planning to deploy its capital through 2027?

    Management targets $3.0-3.3B of free cash flow for 2025-2027. Planned uses include about $1.5B for acquisitions, about $1.0B in dividends with steady annual growth, and about $0.7B in share repurchases intended to offset option dilution. Management says most free cash flow goes back to shareholders, and the plan is consistent with its March 2025 Investor Day.

  3. What growth drivers does management highlight beyond the core lab business?

    Management highlights advanced diagnostics (about $1B in 2025 revenue, with double-digit growth expected), Collaborative Lab Solutions for hospitals (about $800M in 2025, targeted at about $1B in 2026), consumer-initiated and wellness testing through partners such as WHOOP, Oura, and Hims & hers, and a 3% annual productivity and cost savings target under its Invigorate program.

  4. Are the adjusted EPS and margin targets reliable for investors to rely on?

    They are non-GAAP measures, and the company states it cannot reconcile the forward-looking adjusted operating margin and adjusted EPS figures to their GAAP equivalents because special items such as restructuring, integration charges, and amortization are inherently uncertain and could be significant. Investors should review the GAAP results in the company's 10-K and 10-Q filings alongside these projections.

04—Continue

← View all 8-K filings